About Arresto BioSciences
Arresto BioSciences is a company based in Palo Alto (United States) founded in 2007 was acquired by Gilead in December 2010. Arresto BioSciences operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter Palo Alto, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Arresto BioSciences
Detailed funding history for Arresto BioSciences
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Arresto BioSciences
Arresto BioSciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Gilead.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
Locked | Locked | Locked |
Investor details for Arresto BioSciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arresto BioSciences
Investment portfolio details for Arresto BioSciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arresto BioSciences
Detailed financials for Arresto BioSciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arresto Biosciences Comparisons
Peer comparison for Arresto BioSciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arresto BioSciences
Arresto BioSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
Detailed competitors of Arresto BioSciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arresto Biosciences
Complete news archive for Arresto BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arresto BioSciences
Arresto BioSciences was founded in 2007.
Arresto BioSciences is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Arresto Biosciences developed therapeutics for cancer and fibrotic diseases. Its drug candidates targeted enzymes that are involves in the synthesis of the extracellular matrix (ECM). Its lead candidate was a humanized monoclonal antibody that targeted human lysyl oxidase-like-2 (LOXL2) and was in phase I trials for both idiopathic pulmonary fibrosis (IPF) and advanced solid tumors. In Dec 2010, Gilead acquired the company for 225M upfront plus milestone payments.
Arresto BioSciences's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
Arresto BioSciences has 1 investor. Key investors include Gilead.